Resco

Risperidone USP

Composition : Resco-1 : Each tablet contains Risperidone USP 1.0mg.

Resco-2 : Each tablet contains Risperidone USP 2.0mg.

Indications : Resco (Risperidone) is indicated for the treatment of Acute and chronic schizophrenic psychosis, and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness) and/or negative symptoms (such as blunted affect, emotional and social withdrawal, poverty of speech) are prominent. Risperidone also alleviates affective symptoms (such as depression, guilt feelings, anxiety) associated with schizophrenia. Also

indicated at behavioral disturbances in patients with dementia where aggressive symptoms (verbal outbursts, physical violence), activity disturbances (agitation, wandering) or psychotic symptoms are prominent

Dosage and administration : Adults : Resco can be given in 1 or 2 divided doses daily. The usual initial dose of Resco is 2mg on the first day, 4mg on the second day and 6mg on the third day. Further dosage adjustment may be needed and should generally be made at intervals of not less than one week; usual maintenance dose is 4 to 6mg daily. Extrapyramidal symptoms may be more likely with doses above 10mg daily. Behavioral disturbances in patients with dementia : Start 0.25mg b.i.d; adjust by 0.25mg b.i.d, every other day. Optimum 0.5mg b.i.d, some may benefit from 1mg b.i.d. Once target reached, consider once daily dosing. Elderly & renal or liver disease : A starting dose of 0.5mg b.i.d is recommended. This doses can be increased 1 to 2mg b.i.d. Or, as directed by the registered physician.

Use in pregnancy and lactation : Pregnancy category C. It should be used with caution during pregnancy and breast feeding and only if clearly needed.

Packing : Resco-1 : Each box contains 5 x 10's tablets in blister pack.

Resco-2 : Each box contains 5 x 10's tablets in blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.